Omnicell, Inc. — Q1 2023 Form 10-Q
Business context and reporting period. Unaudited results cover the three months ended March 31, 2023, compared with the same period in 2022. Omnicell provides medication-management automation, software, consumables, and services to healthcare providers, and reports as one operating segment.
Key financial results
Amounts are in millions of dollars, except per-share data and percentages.
| Metric | Q1 2023 | Q1 2022 |
|---|---|---|
| Total revenue | $290.6 | $318.8 |
| Gross profit / margin | $125.0 / 43% | $150.0 / 47% |
| Operating income (loss) | $(23.0) | $5.1 |
| Net income (loss) | $(15.0) | $8.2 |
| Diluted EPS | $(0.33) | $0.17 |
| Cash from (used in) operations | $12.8 | $(16.0) |
- Revenue mix: Product revenue was $185.7 million, down 18%; services and other revenue was $104.9 million, up 13%. Connected devices, software licenses, and other revenue was $165.1 million versus $208.1 million; Advanced Services revenue was $51.6 million versus $43.8 million.
- Cash and liquidity: Cash and cash equivalents were $340.4 million at quarter-end, versus $330.4 million at year-end 2022. Working capital was $481.0 million and the current ratio was 2.1. Operating cash flow was positive despite the net loss, supported in part by noncash expenses and increased deferred revenue. Capital expenditures and external-use software development costs totaled $13.6 million.
- Debt: Convertible senior notes had a $575.0 million principal balance and a $567.3 million carrying value, due September 2025, with a 0.25% coupon. The $500 million revolving credit facility had no borrowings; Omnicell reported covenant compliance. The revolver’s benchmark was amended from LIBOR to SOFR in March 2023.
Material changes versus Q1 2022
- Revenue fell 9%, primarily because product revenue declined amid healthcare-system capital-budget constraints. Services growth, driven by Advanced Services demand, installed-base expansion, and pricing, partly offset the decline.
- Gross margin declined four percentage points. Management attributed the pressure mainly to lower product revenue and product costs—particularly labor and overhead—that did not fall proportionally.
- Operating expenses rose 2% to $148.0 million. SG&A increased, including higher facility impairment and restructuring costs, while R&D expense declined.
- Operating cash flow improved from a $16.0 million use to $12.8 million provided. Q1 2023 financing cash flow was $3.9 million provided, compared with $32.1 million used in Q1 2022, when the company repurchased $52.2 million of stock. No shares were repurchased in Q1 2023.
Outlook, risks, and unusual items
- Outlook: The filing provides no numerical quarterly or annual guidance. Management said existing cash, anticipated operating cash flows, employee equity-plan proceeds, and available revolver capacity should meet needs for at least the next 12 months. It expects continued investment in its medication-management platform and cloud-based offerings.
- Cost actions: Headcount was approximately 3,830 at March 31, down from 4,230 at December 31, 2022. The company recorded $5.3 million of employee restructuring costs in Q1 2023 and $22.8 million cumulatively under the plan begun in November 2022. Facility actions generated $7.8 million of lease right-of-use asset impairment and abandonment charges.
- Contingencies: Non-cancelable purchase commitments totaled $122.2 million, with $110.0 million expected to be paid during 2023. A biometric-privacy class action settlement required $4.3 million; final court approval occurred April 6, 2023, and the final installment was paid by April 21. Omnicell said it had no other material accrual for current legal proceedings.
- Other risks: Management highlighted customer capital budgets and installation timing, supply availability, foreign-exchange fluctuations, and the potential effects of the previously disclosed ransomware incident. Cumulative incident expenses were $13.6 million, partly offset by $11.1 million in insurance recoveries, of which $9.6 million had been received. The filing reported no material change to previously disclosed risk factors.
- Disclosure controls were assessed as effective at the reasonable-assurance level; the filing reported no material change in internal control over financial reporting.
Investor verification points
- Track product orders, installation schedules, and healthcare customers’ capital-budget constraints against the continued growth in services revenue.
- Assess whether product margins recover as revenue changes and restructuring and facility actions affect the cost base.
- Review operating cash flow quality, including collections, accrued compensation, and the increase in deferred revenue.
- Monitor restructuring execution, remaining purchase commitments, and the 2025 convertible-note maturity and conversion terms.
- Check subsequent disclosures for developments in ransomware-related recoveries or costs, litigation, and any formal financial guidance.